Bayer Healthcare

For many types of cancer classic chemotherapy is often the only form of treatment available. It functions on the basis of a cytotoxic effect – a cytotoxin kills cancer cells, halting tumor growth. However, these drugs also damage healthy cells and patients may, as a result, suffer severe side effects. With modern cancer therapies physicians are able to target the cancer more precisely.

They include the recently developed approach of antibody-drug conjugates (ADC). This new approach attacks the cancer in a much more targeted way and healthy cells are less severely affected.

Bayer HealthCare currently has several projects using this approach in its research pipeline. The company has the worldwide rights to utilize Seattle Genetics’ auristatin-based ADC technology with antibodies to several oncology targets.

MabPlex
 

6 West Belt
Wayne, NJ 07470
U.S.A

Web: Bayer HealthCare